Document is current
Any future updates will be listed below
-
Authors
Ni, Jason R.
Quirk, Matthew
Chmielowski, Bartosz
Padia, Siddharth A. https://orcid.org/0000-0002-3975-7479
- License Information
-
More Information
Article History
Received: 21 October 2025
Accepted: 31 January 2026
First Online: 20 February 2026
Declarations
:
: Jason R. Ni: None. Matthew Quirk: None. Bartosz Chmielowski: Advisory Board: Treeline Biosciences, Fortvita Biologics, Immunocore. Data Monitoring Committee: Servier, SpringWorks Therapeutics, TuHura. Clinical Trial Support: Bristol-Myers Squibb, Macrogenics, Infinity Pharmaceuticals, Advenchen Laboratories, Xencor, Compugen, Iovance, RAPT Therapeutics, IDEAYA Biosciences, Ascentage, Atreca, Replimune, InstilBio, Adagene, TriSalus Life Sciences, Kinnate, PTC Therapeutics, Xilio Therapeutics, Kezar Life Sciences, Immunocore, AskGene Pharma, Krystal bio, Nested Therapeutics, Pierre Fabre, Georgiamune, Immatics, Regeneron. Siddharth A. Padia: Consultant for Boston Scientific, Teleflex, Varian Medical Systems, Terumo, Next Medical, Crannmed, Easai, Johnson and Johnson, Merit, Philips, BD, Asahi, and Delcath. Research grant: Varian and Boston Scientific.
: This study has obtained IRB approval from the UCLA Human Research Protection Program (IRB Approval #23–000622) and the need for informed consent was waived.
: For this type of study, formal consent is not required.
: For this type of study consent for publication is not required.
